<DOC>
	<DOCNO>NCT00602862</DOCNO>
	<brief_summary>Sorafenib tyrosine kinase inhibitor register treatment metastasize clear cell Renal Cell Carcinoma ( ccRCC ) . It inhibit signal transduction Vascular Endothelial Growth Factor Receptor ( VEGFR ) Platelet Derived Growth Factor Receptor ( PDGFR ) . In tumorigenesis ccRCC , VEGF PDGF upregulated due defective Von-Hippel-Lindau ( VHL ) gene . CcRCC high Interstitial Fluid Pressure ( IFP ) Tumor Microvascular Density ( TMD ) , hamper delivery chemotherapeutics monoclonal antibody ( mAbs ) . It hypothesize antiangiogenic compound decrease tumor IFP TMD , thus normalize tumor vasculature , diminish tumor vasculature . Bevacizumab anti-VEGF mAb deplete soluble VEGF plasma , deprive VEGFR ligand . Chimeric monoclonal antibody cG250 recognize carbonic anhydrase IX ( CAIX ) , antigen abundantly express Renal Cell Carcinoma ( RCC ) limit expression normal tissue . The aim study investigate effect Sorafenib ccRCC physiology , determine tumor uptake 111In label cG250 111In label Bevacizumab .</brief_summary>
	<brief_title>Effect Sorafenib ccRCC Uptake Radiolabeled Bevacizumab cG250</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Renal cell carcinoma patient plan surgery ( nephrectomy/metastasectomy ) Karnofsky &gt; 70 % Laboratory value within 14 day prior start : White blood cell ( WBC ) &gt; 3.5 x 109/L Platelets &gt; 100 x 109/L Hemoglobin &gt; 6 mmol/L Total bilirubin &lt; 1.5 upper limit normal ( ULN ) ASAT , ALAT &lt; 2.5 x ULN ( &lt; 5 x case liver metastasis ) Lactate dehydrogenase ( LDH ) &gt; 1.5 . ULN Serum creatinine &lt; 2 x ULN Amylase Lipase &lt; 1.5 ULN Negative pregnancy test premenopausal woman Age 18 year Signed inform consent Life expectancy &gt; 24 week PT/APTT/ INR &lt; 1.5 ULN No current use coumarin derivative Known subtype clear cell RCC Preexposure murine/chimeric antibody therapy Known brain metastasis Untreated hypercalcemia Uncontrolled hypertension Concurrent therapeutic anticoagulation Chemotherapy , immunotherapy radiation therapy within 4 week prior start study . Palliative limit field external radiation fracture prevention allow Cardiac arrhythmia require antiarrhythmic ( betablockers , digoxin ) , symptomatic coronary artery disease congestive heart failure New York Heart Association III IV . Previous malignancy &lt; 2 year prior study ( except cervical carcinoma situ , basal cell carcinoma , superficial bladder tumour ( Ta , Tis , T1 ) Any medical condition present opinion investigator affect patient ' clinical status . No concurrent malignancy except nonmetastatic nonmelanoma skin cancer carcinoma situ cervix . Active clinically serious bacterial fungal infection ( &lt; grade 2 NCICTC version 3 ) Known history Human Immunodeficiency virus ( HIV ) infection chronic hepatitis B/C . Prior use Rafkinase inhibitor , MEK Farnesyl transferase inhibitor Prior use Bevacizumab drug target VEGF/ VEGFreceptors Use antiepileptic drug Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Angiogenesis inhibitor</keyword>
</DOC>